AZD-8421
- Generic Name
- AZD-8421
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- High-grade Serous Ovarian Cancer (HGSOC)ER+ HER2- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 348
- Registration Number
- NCT06188520
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath